Fig. 6From: Anti-fibrotic efficacy of nintedanib in pulmonary fibrosis via the inhibition of fibrocyte activityNintedanib inhibits the migration of fibrocytes induced by growth factors. Fibrocytes were added to the upper chamber in the presence or absence of various concentrations of nintedanib (a, b), BGJ398 (a), imatinib (b), or SU5416 (c). A total of 30 ng/ml of FGF2 (a), 100 ng/ml of PDGF-BB (b), or 100 ng/ml of VEGF-A (c) was added to the lower chamber. After a 20-h incubation, fibrocytes that had migrated to the bottom surface of the filter were counted in 5 random fields per section at 100× magnification. Data were analyzed using the Kruskal-Wallis H test and displayed as median and interquartile range of three separate experiments (n = 15 in each group). In all graphs: *P < 0.05 versus the group treated with growth factors (FGF2, PDGF-BB, or VEGF-A) alone. HPF; high-power fieldsBack to article page